Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 345 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer's Disease(AD) Clear all
Completed Phase 4 Interventional

A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease

NCT01122329
View directory record Official record
Conditions
Alzheimer Disease
Interventions
caprylidene, Placebo
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 8, 2026, 2:21 AM EDT
Active, not recruiting Early Phase 1 Interventional

Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease

NCT03560960
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Pramlintide challenge test
Drug
Lead sponsor
Boston University
Other
Eligibility
60 Years to 90 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 8, 2026, 2:21 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

NCT01466088
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil, AZD3480
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Phoenix, Arizona • Brooksville, Florida • Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 8, 2026, 2:21 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Bapineuzumab In Alzheimer Disease Subjects

NCT00663026
View directory record Official record
Conditions
Alzheimer Disease
Interventions
bapineuzumab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 89 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
17
States / cities
Phoenix, Arizona • Sun City, Arizona • Encino, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2013 · Synced Oct 8, 2026, 2:21 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

NCT06335173
View directory record Official record
Conditions
Alzheimer Disease
Interventions
sabirnetug, Placebo
Drug
Lead sponsor
Acumen Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Carlsbad, California • Fullerton, California • Irvine, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 8, 2026, 2:21 AM EDT
Completed No phase listed Observational

EEG/ERP Longitudinal Study in Alzheimer's Disease (AD)

NCT02769234
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ERP/EEG test, Psychometric testing
Procedure
Lead sponsor
Neuronetrix, Inc.
Industry
Eligibility
60 Years to 95 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
West Palm Beach, Florida • Brookline, Massachusetts • Bennington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 8, 2026, 2:21 AM EDT
Completed Phase 1 Interventional

Computer-Based Training for Mild Alzheimer's Disease

NCT00319891
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Computer-based Cognitive Training
Procedure
Lead sponsor
Posit Science Corporation
Industry
Eligibility
60 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 8, 2026, 2:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Simvastatin on Biomarkers

NCT01142336
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Simvastatin, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
45 Years to 64 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 8, 2026, 2:21 AM EDT
Terminated Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).

NCT02670083
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Crenezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
66
States / cities
Phoenix, Arizona • Encino, California • Long Beach, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 8, 2026, 2:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Imaging in Alzheimer's Disease

NCT00039702
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123] 5-I-A-85380
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 8, 2026, 2:21 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Neuroinflammation Imaging in AD

NCT04274998
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteer
Interventions
[18F]NOS, [11C]PBR28
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 8, 2026, 2:21 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects

NCT03935568
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PU-AD, Placebo
Drug
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 8, 2026, 2:21 AM EDT
Terminated Phase 2 Interventional Results available

Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI

NCT01812213
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
[18F]NAV4694
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
55 Years to 99 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Sun City, Arizona • Hialeah, Florida • Miami Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 8, 2026, 2:21 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD

NCT04931459
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ACU193, Placebo
Drug
Lead sponsor
Acumen Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Scottsdale, Arizona • Anaheim, California • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 8, 2026, 2:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

NCT02370524
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
[18F]T807
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
20 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 8, 2026, 2:21 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Brain NAD in Alzheimer's Disease

NCT07127510
View directory record Official record
Conditions
Alzheimer Disease (AD)
Interventions
Not listed
Lead sponsor
Florida Atlantic University
Other
Eligibility
65 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 8, 2026, 2:21 AM EDT
Recruiting Early Phase 1 Interventional

Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

NCT06932809
View directory record Official record
Conditions
Tauopathies
Interventions
18F-JSS20-183A PET, Brain MRI, Amyloid PET, Neurological Assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 8, 2026, 2:21 AM EDT
Terminated Phase 3 Interventional

LIFE-DSR-Biomarker Sub-study of Biomarkers in Down Syndrome Related Alzheimer's Disease (DS-AD)

NCT06860373
View directory record Official record
Conditions
Down Syndrome
Interventions
[18F]MK-6240
Biological
Lead sponsor
LuMind IDSC Foundation
Other
Eligibility
35 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 8, 2026, 2:21 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT05552157
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Remternetug (SC), Matching Placebo (Remternetug)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
13
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 8, 2026, 2:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)

NCT02754830
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 8, 2026, 2:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD

NCT03389698
View directory record Official record
Conditions
Alzheimer Disease
Interventions
GRASP Dynamic Contrast-Enhanced (DCE) MRI, 3T Brain Scan, Gadolinium-based Contrast Agent (GBCA) for MRI
Device · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
20 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 8, 2026, 2:21 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

NCT05344989
View directory record Official record
Conditions
Healthy Volunteers, Tauopathies, Alzheimer Disease
Interventions
APNmAb005, Placebo
Drug
Lead sponsor
APRINOIA Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 8, 2026, 2:21 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

NCT04602624
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Dysfunction, Mild Dementia
Interventions
SAGE-718
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Redlands, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 8, 2026, 2:21 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

NCT02624778
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3002813, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Delray Beach, Florida • Orlando, Florida • The Villages, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 8, 2026, 2:21 AM EDT